These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 17604674)

  • 1. [Pulse dose-rate brachytherapy and treatment of uterine cervix cancer: impact of a 3D or a 2D dosimetric support].
    Tournat H; Chilles A; Charra-Brunaud C; Peiffert D; Ahmad F; Métayer Y
    Cancer Radiother; 2007 Jun; 11(4):188-96. PubMed ID: 17604674
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Physics contributions and clinical outcome with 3D-MRI-based pulsed-dose-rate intracavitary brachytherapy in cervical cancer patients.
    Chargari C; Magné N; Dumas I; Messai T; Vicenzi L; Gillion N; Morice P; Haie-Meder C
    Int J Radiat Oncol Biol Phys; 2009 May; 74(1):133-9. PubMed ID: 18774656
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MRI-guided 3D optimization significantly improves DVH parameters of pulsed-dose-rate brachytherapy in locally advanced cervical cancer.
    Lindegaard JC; Tanderup K; Nielsen SK; Haack S; Gelineck J
    Int J Radiat Oncol Biol Phys; 2008 Jul; 71(3):756-64. PubMed ID: 18191335
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical impact of computed tomography-based image-guided brachytherapy for cervix cancer using the tandem-ring applicator - the Addenbrooke's experience.
    Tan LT; Coles CE; Hart C; Tait E
    Clin Oncol (R Coll Radiol); 2009 Apr; 21(3):175-82. PubMed ID: 19101130
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation of dose-volume parameters, endoscopic and clinical rectal side effects in cervix cancer patients treated with definitive radiotherapy including MRI-based brachytherapy.
    Georg P; Kirisits C; Goldner G; Dörr W; Hammer J; Pötzi R; Berger D; Dimopoulos J; Georg D; Pötter R
    Radiother Oncol; 2009 May; 91(2):173-80. PubMed ID: 19243846
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Radiotherapy doses at special reference points correlate with the outcome of cervical cancer therapy.
    Yoshimura R; Hayashi K; Ayukawa F; Toda K; Iwata M; Oota S; Hoshi A; Wakatsuki M; Kurosaki H; Okazaki A; Shibuya H
    Brachytherapy; 2008; 7(3):260-6. PubMed ID: 18579445
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radical radiotherapy with high-dose-rate brachytherapy for uterine cervix cancer long-term results.
    Khor TH; Tuan JK; Hee SW; Tham IW
    Australas Radiol; 2007 Dec; 51(6):570-7. PubMed ID: 17958695
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Innovation in gynaecological brachytherapy: new technologies, pulse dose-rate brachytherapy, image, definition of new volumes of interest and their impact on dosimetry: application in a clinical research programme "STIC"].
    Haie-Meder C; Peiffert D
    Cancer Radiother; 2006 Nov; 10(6-7):402-9. PubMed ID: 16884941
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potential of dose optimisation in MRI-based PDR brachytherapy of cervix carcinoma.
    De Brabandere M; Mousa AG; Nulens A; Swinnen A; Van Limbergen E
    Radiother Oncol; 2008 Aug; 88(2):217-26. PubMed ID: 18037524
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preoperative concurrent radiation therapy and chemotherapy for bulky stage IB2, IIA, and IIB carcinoma of the uterine cervix with proximal parametrial invasion.
    Huguet F; Cojocariu OM; Levy P; Lefranc JP; Darai E; Jannet D; Ansquer Y; Lhuillier PE; Benifla JL; Seince N; Touboul E
    Int J Radiat Oncol Biol Phys; 2008 Dec; 72(5):1508-15. PubMed ID: 18676093
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patterns of care and outcome in elderly cervical cancer patients: a special focus on brachytherapy.
    Magné N; Mancy NC; Chajon E; Duvillard P; Pautier P; Castaigne D; Lhommé C; Morice P; Haie-Meder C
    Radiother Oncol; 2009 May; 91(2):197-201. PubMed ID: 18954913
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intraoperative real-time planned conformal prostate brachytherapy: post-implantation dosimetric outcome and clinical implications.
    Zelefsky MJ; Yamada Y; Cohen GN; Sharma N; Shippy AM; Fridman D; Zaider M
    Radiother Oncol; 2007 Aug; 84(2):185-9. PubMed ID: 17692978
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Critical organ preservation in reirradiation brachytherapy by injectable spacer.
    Kishi K; Sonomura T; Shirai S; Sato M; Tanaka K
    Int J Radiat Oncol Biol Phys; 2009 Oct; 75(2):587-94. PubMed ID: 19735885
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Single versus customized treatment planning for image-guided high-dose-rate brachytherapy for cervical cancer: dosimetric comparison and predicting factor for organs at risk overdose with single plan approach.
    Chi A; Gao M; Sinacore J; Nguyen NP; Vali F; Albuquerque K
    Int J Radiat Oncol Biol Phys; 2009 Sep; 75(1):309-14. PubMed ID: 19540070
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Magnetic resonance imaging-guided intracavitary brachytherapy for cancer of the cervix.
    Zwahlen D; Jezioranski J; Chan P; Haider MA; Cho YB; Yeung I; Levin W; Manchul L; Fyles A; Milosevic M
    Int J Radiat Oncol Biol Phys; 2009 Jul; 74(4):1157-64. PubMed ID: 19101097
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Persistently better treatment planning results of intensity-modulated (IMRT) over conformal radiotherapy (3D-CRT) in prostate cancer patients with significant variation of clinical target volume and/or organs-at-risk.
    Fenoglietto P; Laliberte B; Allaw A; Ailleres N; Idri K; Hay MH; Moscardo CL; Gourgou S; Dubois JB; Azria D
    Radiother Oncol; 2008 Jul; 88(1):77-87. PubMed ID: 18215434
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pulsed reduced dose-rate radiotherapy: a novel locoregional retreatment strategy for breast cancer recurrence in the previously irradiated chest wall, axilla, or supraclavicular region.
    Richards GM; Tomé WA; Robins HI; Stewart JA; Welsh JS; Mahler PA; Howard SP
    Breast Cancer Res Treat; 2009 Mar; 114(2):307-13. PubMed ID: 18389365
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation between dosimetric parameters and late rectal and urinary toxicities in patients treated with high-dose-rate brachytherapy used as monotherapy for prostate cancer.
    Konishi K; Yoshioka Y; Isohashi F; Sumida I; Kawaguchi Y; Kotsuma T; Adachi K; Morimoto M; Fukuda S; Inoue T
    Int J Radiat Oncol Biol Phys; 2009 Nov; 75(4):1003-7. PubMed ID: 19345517
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Late chest wall toxicity after MammoSite breast brachytherapy.
    Brashears JH; Dragun AE; Jenrette JM
    Brachytherapy; 2009; 8(1):19-25. PubMed ID: 18955019
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Twice-daily high-dose-rate brachytherapy for medically inoperable uterine cancer.
    Gerszten K; Faul C; Kelley J; Selvaraj R; King GC; Mogus R; Heron D
    Brachytherapy; 2006; 5(2):118-21. PubMed ID: 16644466
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.